StageZero Reports Reduced Q1 Loss, Expands Partnerships
Company Announcements

StageZero Reports Reduced Q1 Loss, Expands Partnerships

Stagezero Life Sciences (TSE:SZLS) has released an update.

StageZero Life Sciences has reported a decline in its Q1 2024 revenue to $0.523 million from the previous year’s $0.778 million, but also noted a significant reduction in net loss to $0.386 million from $1.812 million. The company highlighted advancements in partnerships and business development in North America and Europe, with a strategic focus on its proprietary Aristotle multi-cancer screening test and the upcoming launch of the COC Protocol 2.0.

For further insights into TSE:SZLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskStageZero Life Sciences Reports Q2 Growth, Eyes Expansion
TipRanks Canadian Auto-Generated NewsdeskStageZero Nears Filing Full Year 2023 Financials Amid Trading Halt
TipRanks Canadian Auto-Generated NewsdeskStageZero Faces Trading Halt Amid Financial Filing Delay
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App